Consequently, these two molecules were identified in silico as potential multi-target candidates against the enzymes AChE, BuChE, and MAO-B, primarily involved in AD pathology, based on an in-depth in silico study aimed at minimizing drug development costs and time. Here, MAOB is linked to Alzheimer disease.